 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Advances in preclinical/clinical glioblastoma treatment : |
(Institut Català de Nanociència i Nanotecnologia) (Institut Català de Nanociència i Nanotecnologia) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) (Institut d'Investigació Biomèdica de Bellvitge) (Universitat Autònoma de Barcelona. Institut de Neurociències) (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Universitat Autònoma de Barcelona. Departament de Química)
| Data: | 2022 |
| Resum: | Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim. |
| Ajuts: | European Commission 777222 Ministerio de Ciencia e Innovación PID2020-113058GB-I00 Ministerio de Ciencia e Innovación RTI2018-098027-B-C22 Ministerio de Ciencia e Innovación RTI2018-098027-B-C21 Ministerio de Ciencia e Innovación RED2018-102471-T Ministerio de Ciencia e Innovación SEV-2017-0706 |
| Nota: | Altres ajuts: This work was supported by ERDF A way of making Europe and by PI21/00181 from the Instituto Carlos III. The ICN2 and IDIBELL are funded by the CERCA programme/Generalitat de Catalunya. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 "Cancer nanomedicine from the bench to the bedside". This work was also supported by the Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship. |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Glioblastoma ; Preclinical model ; Nanoparticles ; Drug delivery ; Brain cancer ; BBB |
| Publicat a: | Cancers, Vol. 14, issue 19 (Oct. 2022) , art. 4960, ISSN 2072-6694 |
